Status:
COMPLETED
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity
Lead Sponsor:
Ministry of Health and Population, Egypt
Conditions:
Obesity
Eligibility:
All Genders
30-55 years
Brief Summary
The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group). .
Detailed Description
The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group). Materi...
Eligibility Criteria
Inclusion
- stable weight in the previous 6 months.
- a sedentary lifestyle.
- no history of diabetes mellitus.
- taking medication that affects appetite, or weight within the past 6 months
Exclusion
- severe anemia
- hypothyroidism and hyperthyroidism
- Diabetes mellitus
- moderate to severe liver or kidney disease
- body mass index less than 30
Key Trial Info
Start Date :
January 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 29 2019
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04043702
Start Date
January 4 2019
End Date
July 29 2019
Last Update
August 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mahmoud Younis
Cairo, Egypt, 11759